Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Common shares of Psyched Wellness (PSYC) are now eligible for electronic clearing and settlement through the DTC
  • Shares will continue to trade under the ticker symbol PSYCF on the OTCQB
  • DTC eligibility allows Psyched shares to be accessible to an even broader range of investors
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
  • Psyched Wellness (PSYC) is up 4 per cent, trading at C$0.26 per share at 12 pm ET

Common shares of Psyched Wellness (PSYC) are now eligible for electronic clearing and settlement through the DTC.

The Depository Trust Company (DTC) manages the electronic clearing and settlement of publicly traded companies in the United States.

Psyched common shares are now fully DTC eligible and will continue to trade under the ticker symbol PSYCF on the OTCQB.

Through an electronic method of clearing securities, DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States.

Jeff Stevens, CEO, comments,

“By achieving DTC eligibility, Psyched shares become more accessible to an even broader range of investors. This important milestone will strengthen our U.S. and global shareholder base and increase the liquidity of our common shares to the benefit of all investors. Psyched stock is now traded in Canada (PSYC), Germany (5U9) and the United States (PSYCF) positioning the Company in both domestic and international markets to continue to grow a global investor base.”

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness (PSYC) is up 4 per cent, trading at C$0.26 per share at 12 pm ET.

More From The Market Herald

" Marvel Biosciences (TSXV:MRVL) developing novel non-hallucinogenic neuroplastic promoting compounds

Marvel Biosciences (MRVL) has launched a program to identify and develop agents that promote neuroplasticity without the risks or side effects of psychedelics.

" Entheon Biomedical (CSE:ENBI) provides corporate update

Entheon Biomedical (ENBI) is pleased to provide an update on its operations and progress on its strategic initiatives.
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.